Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice
NCT ID: NCT03042390
Last Updated: 2020-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
762 participants
OBSERVATIONAL
2016-12-23
2017-05-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS
NCT03683524
Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy
NCT00611039
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569
Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients
NCT02039921
Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice
NCT01375881
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DArunavir/cobicistat
Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inform consent document.
* To have initiated therapy containing DRV / c and have a follow-up of at least 24 Weeks.
Exclusion Criteria
* Patients not routinely followed in the center
* Patient less than 18 years of age.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag, S.A.
INDUSTRY
Fundacion SEIMC-GESIDA
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Costa del Sol
Málaga, Marbella, Spain
Hospital Clinic i Provincial
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital del Mar
Barcelona, , Spain
Hospital del Vall d'Hebron
Barcelona, , Spain
Hospital Germans Trias i Pujol
Barcelona, , Spain
Hospital de Guadalajara
Guadalajara, , Spain
Hospital Infanta Leonor
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital La Princesa
Madrid, , Spain
Hospital Príncipe de Asturias
Madrid, , Spain
Hospital Puerta de Hierro
Madrid, , Spain
Hospital Ramón y Cajal
Madrid, , Spain
Hospital Virgen de la Victoria
Málaga, , Spain
Hospital de Son Llatzer
Palma de Mallorca, , Spain
Hospital de Valme
Seville, , Spain
Complejo Hospitalario de Toledo
Toledo, , Spain
Hospital Clínico de Valencia
Valencia, , Spain
Hospital La Fe
Valencia, , Spain
Complejo Hospitalaria Alvaron Cunqueiro
Vigo, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perez Elias MJ, Alejos B, Gutierrez MM, Crespo M, De Los Santos Gil I, Ribera E, Galindo MJ, Lozano F, Payeras Cifre A, Boix V, Montero-Alonso M, Sanz J, De La Torre Lima J, Palacios R, De La Fuente Moral S, Martinez E; Codar Study Group. Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. J Antimicrob Chemother. 2021 Mar 12;76(4):1046-1050. doi: 10.1093/jac/dkaa547.
Perez Elias MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, Garcia-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo Garcia MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepulveda MA, Troya J, Del Campo S, Martinez E; CODAR study group. Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316). J Antimicrob Chemother. 2019 Oct 1;74(10):3044-3048. doi: 10.1093/jac/dkz254.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GESIDA 9316
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.